Monte Rosa Therapeutics, Inc. Payments for Repurchase of Initial Public Offering
Monte Rosa Therapeutics, Inc. (GLUE) reported Payments for Repurchase of Initial Public Offering of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-16.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsForRepurchaseOfInitialPublicOffering · last filed 2023-03-16
- Monte Rosa Therapeutics, Inc. payments for repurchase of initial public offering for the quarter ending 2022-12-31 was $0.00, a 100.00% decline year-over-year.
- Monte Rosa Therapeutics, Inc. payments for repurchase of initial public offering for the quarter ending 2022-09-30 was $0.00, a 100.00% decline year-over-year.
- Monte Rosa Therapeutics, Inc. payments for repurchase of initial public offering for the quarter ending 2021-12-31 was $156.00K.
- Monte Rosa Therapeutics, Inc. payments for repurchase of initial public offering for the quarter ending 2021-09-30 was $1.55M.
- Monte Rosa Therapeutics, Inc. payments for repurchase of initial public offering for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- Monte Rosa Therapeutics, Inc. payments for repurchase of initial public offering for fiscal 2021 was $3.11M.
| Period end | Payments for Repurchase of Initial Public Offering 3 month | Payments for Repurchase of Initial Public Offering 6 month | Payments for Repurchase of Initial Public Offering 9 month | Payments for Repurchase of Initial Public Offering 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $0.00 derived: sum of 2 quarters · filed 2023-03-16 | $0.00 10-K · filed 2023-03-16 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $0.00 10-Q · filed 2022-11-10 | ||
| 2022-06-30 | $0.00 10-Q · filed 2022-08-11 | |||
| 2021-12-31 | $156.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $1.71M derived: sum of 2 quarters · filed 2023-03-16 | $3.11M 10-K · filed 2023-03-16 | |
| 2021-09-30 | $1.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $2.95M 10-Q · filed 2022-11-10 | ||
| 2021-06-30 | $1.40M 10-Q · filed 2022-08-11 | |||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $0.00 10-Q · filed 2021-11-10 | ||
| 2020-06-30 | $0.00 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |